Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Aldesleukin + Pembrolizumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Aldesleukin||Proleukin||IL-2|Interleukin-2|IL2||Aldesleukin (IL-2) is a cytokine that potentially modulates antitumor immune response (NCI Drug Dictionary).|
|Pembrolizumab||Keytruda||MK-3475||Immune Checkpoint Inhibitor 141 PD-L1/PD-1 antibody 83||Keytruda (pembrolizumab) is an antibody against PD-1 that activates T-cell mediated anti-tumor immune response (PMID: 25977344). Keytruda (pembrolizumab) is approved in melanoma, SCLC, HNSCC, classical Hodgkin Lymphoma, primary mediastinal large B-cell lymphoma, urothelial carcinoma, HCC, Merkel cell carcinoma, NMIBC, cutaneous squamous cell carcinoma, MSI-H or dMMR or TMB high advanced solid tumors, CD274 (PD-L1)-expressing NSCLC, gastric and GEJ adenocarcinoma, squamous esophageal carcinoma, cervical cancer, and triple-negative breast cancer, in combination with pemetrexed and platinum in non-squamous NSCLC with no EGFR or ALK mutations, with carboplatin and paclitaxel/nab-paclitaxel in squamous NSCLC, with axitinib or lenvatinib in RCC, with Lenvatinib in endometrial carcinoma that is not MSI-H or dMMR, in combination with platinum and fluoropyrimidine-based chemotherapy for patients with esophageal or gastroesophageal carcinoma, in combination with Herceptin (trastuzumab), fluoropyrimidine- and platinum-containing chemotherapy for first-line treatment of patients with HER2-positive gastric or gastroesophageal junction adenocarcinoma, and in combination with platinum-based chemotherapy, with or without bevacizumab, for patients with CD274 (PD-L1)-expressing (CPS>=1) cervical cancer (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT02748564||Phase II||Aldesleukin + Pembrolizumab||Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma||Active, not recruiting||USA||0|
|NCT03260504||Phase I||Aldesleukin + Pembrolizumab||Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer||Recruiting||USA||0|
|NCT03111901||Phase Ib/II||Aldesleukin + Pembrolizumab||Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer||Withdrawn||USA||0|
|NCT02964078||Phase II||Aldesleukin + Pembrolizumab||Interleukin-2 and Pembrolizumab for Metastatic Kidney Cancer||Active, not recruiting||USA||0|
|NCT05155033||Phase II||Aldesleukin + Pembrolizumab||Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma||Recruiting||USA||0|
|NCT03476174||Phase II||Aldesleukin + Pembrolizumab||Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma||Terminated||USA||0|
|NCT03546426||Phase I||Aldesleukin + Pembrolizumab||Pembrolizumab Plus Autologous Dendritic Cell Vaccine in Patients With PD-L1 Negative Advanced Mesothelioma Who Have Failed Prior Therapies (MESOVAX)||Recruiting||ITA||0|